Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.59 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759213 | 1.00 | HCAR1 (0.59) | HCAR1HCAR2POLBTTRCES2 | |
| Hydrochloric Acid SCHEMBL5226036 | 0.98 | HCAR1 (0.57) | HCAR1HCAR2POLBTTRCES2 | |
| SCHEMBL22289143 | 0.84 | HCAR1 (0.49) | HCAR1HCAR2POLBTTRCES2 | |
| SCHEMBL157714 | 0.83 | HCAR1 (0.73) | HCAR1HCAR2TTRCES2CES1 | |
| SCHEMBL475757 | 0.83 | TTR (0.56) | HCAR1HCAR2POLBTTRCA12 | |
| SCHEMBL23501889 | 0.83 | TTR (0.56) | HCAR1HCAR2POLBTTRCA12 | |
| SCHEMBL336433 | 0.83 | HCAR1 (0.73) | HCAR1HCAR2TTRCES2CES1 | |
| SCHEMBL8361 | 0.83 | TTR (0.56) | HCAR1HCAR2POLBTTRCA12 | |
| SCHEMBL28429976 | 0.82 | HCAR1 (0.42) | HCAR1HCAR2POLBTTRCES2 | |
| Hydrochloric Acid SCHEMBL11153457 | 0.80 | TTR (0.54) | HCAR1HCAR2POLBTTRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-22 | — | — | US | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-04-29 | — | — | US | disclosed |
| EP-4525873-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | Biomea Fusion, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025056017-A1 | FUSED BICYCLIC HETEROARYLS AS PARG INHIBITORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2025-03-20 | — | — | WO | disclosed |
| US-20250074900-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-06 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| WO-2003084917-A1 | (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-6586633-B1 | Antifungal agents | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
| EP-1112998-A1 | AMINE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-07-04 | — | — | EP | disclosed |
| CN-1152853-A | Fungicidal compositions based on 3-phenylpyrazole derivatives for treating plant propagation material, novel 3-phenylpyrazole derivatives and their fungicidal use | RHONE POULENC AGROCHIMIE (FR) | 1997-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | HCAR1 3095/4885HCAR2 3315/4885POLB 1379/4885 |
| US-12286422-B2 | Methods and compositions of 4-substituted benzoylpiperazine-1-substituted carbonyls as β-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | HCAR1 4018/4885HCAR2 4190/4885POLB 3878/4885 |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | PTGES2, PTGIR, PTGES | HCAR1 102/4885HCAR2 51/4885POLB 1534/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | HCAR1 4259/4885HCAR2 4180/4885POLB 165/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | HCAR1 65/4885HCAR2 62/4885POLB 3928/4885 |
| US-20250074900-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | HCAR1 607/4885HCAR2 912/4885POLB 874/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | HCAR1 131/4885HCAR2 150/4885POLB 3968/4885 |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | FLT3, MEN1, FEM1B | HCAR1 2257/4885HCAR2 3155/4885POLB 666/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | HCAR1 930/4885HCAR2 700/4885POLB 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.